Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label tusamitamab ravtansine in CEACAM5-negative or moderate NSQ NSCLC with high circulating CEA
jRCT2011220001Phase 2Completed
- Sponsor
- Sanofi
- Start
- Sep 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of tusamitamab ravtansine in Non-small cell lung cancer (NS-NSCLC), sponsored by Sanofi. Primary endpoint: Objective response rate (ORR). Started Sep 2023; status: completed.
02
Drugs
tusamitamab ravtansine
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on jRCT2011220001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011220001.